Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study

This study was conducted to determine the maximum tolerated dose and dose-limiting toxicity of irinotecan (CPT-11) administered every 3 weeks to adults with progressive malignant glioma who were treated with enzyme-inducing antiepileptic drug (EIAED) therapy, and to compare the pharmacokinetics with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Prados, Michael D., Yung, W.K.A., Jaeckle, Kurt A., Robins, H. Ian, Mehta, Minesh P., Fine, Howard A., Wen, Patrick Y., Cloughesy, Timothy F., Chang, Susan M., Nicholas, M. Kelly, Schiff, David, Greenberg, Harry S., Junck, Larry, Fink, Karen L., Hess, Kenneth R., Kuhn, John
Format: Artigo
Idioma:Inglês
Publicat: Duke University Press 2004
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1871968/
https://ncbi.nlm.nih.gov/pubmed/14769140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/S1152851703000292
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars